ABSTRACT: Glycocins (glycosylated bacteriocins) are a family of ribosomally synthesized and post-translationally modified peptides with antimicrobial activities against pathogens of interest, including methicillin−resistant Staphylococcus aureus, representing a promising source of new antibiotics. Glycocins are still largely underexplored, and thus far, only six glycocins are known. Here, we used genome mining to identify 50 putative glycocin biosynthetic gene clusters and then chose six of them with distinct features for further investigation. Through two rounds of plug-and-play pathway refactoring and expression in Escherichia coli BL21(DE3), four systems produced novel glycocins. Further structural characterization revealed that one of them, which belongs to the enterocin 96-type glycocins, was diglucosylated on a single serine. The other three compounds belong to the SunA/ThuA-type glycocins and exhibit a antimicrobial spectrum narrower than that of sublancin, the best characterized member in this group, even though they share a similar disulfide topology and glycosylation. Further evaluation of their bioactivities with free glucose at high concentrations suggested that their antimicrobial mechanisms might be both glycocin-and species-specific. These glycocins with distinct features significantly broaden our knowledge and may lead to the discovery of new classes of antibiotics.
R ibosomally synthesized and post-translationally modified peptides (RiPPs) constitute an emerging family of natural products with various structural features and bioactivities. 1 Glycocins (glycosylated bacteriocins) are a group of RiPPs that feature sugar moieties installed on serine, threonine, or cysteine residues and two nested disulfide bonds that stabilize their helix−loop−helix structures. A typical biosynthetic pathway for glycocin involves five genes. The gene encoding the precursor peptide is expressed first, and the resulting precursor peptide is then glycosylated by a glycosyltransferase. Two disulfide oxidoreductases are responsible for forming the disulfide bonds, and a bifunctional transporter transfers the peptide outside the cell and removes the leader peptide. 2 Four groups of glycocins with distinct scaffolds have been discovered to date, with the prototypes being glycocin F (GccF-type), sublancin (SunA/ThuA type), enterocin 96 (enterocin 96-type), and enterocin F4-9 (enterocin F4-9-type) ( Figure S1b ). 2 Owing to recent advances in next-generation sequencing and bioinformatics, many putative glycocin biosynthetic gene clusters (BGCs) have been identified through genome mining. However, only six glycocins have been discovered so far: five isolated from native producers and one by chemoenzymatic synthesis. 2 This dearth of characterized glycocins may be attributed to our limited knowledge of glycocins and technical challenges in product isolation from the native producers, particularly pathogens and extremophiles. All six known glycocins show antimicrobial bioactivities against several Gram-positive pathogens such as Bacillus cereus, Streptococcus pyogenes, and Staphylococcus aureus. One of them, sublancin, was also active against drug resistant strains such as methicillinresistant S. aureus (MRSA) and gentamicin-resistant Enterococcus faecalis.
3−5 Therefore, glycocins appear to be a promising source for drug leads, 3, 6 and it is desirable to discover novel glycocins.
In this work, we sought to use a synthetic biology approach based on the pathway refactoring strategy we previously developed 7 to rapidly discover new glycocins. RODEO (rapid ORF description and evaluation online), 8 a powerful genome mining tool for RiPPs, was used for predicting putative glycocin BGCs. According to their distinct features, six putative glycocin BGCs were chosen for pathway refactoring in Escherichia coli. Four of them successfully produced new glycocins, which were named bacillicin CER074, bacillicin BAG2O, geocillicin, and listeriocytocin. These glycocin BGCs originate from various species with most of them either pathogens or extremophiles, but our synthetic biology strategy involving DNA synthesis and pathway refactoring in E. coli has made the glycocin discovery process rapid and scalable.
■ RESULTS AND DISCUSSION
Design of a Modified Pathway Refactoring Workflow. Previously, we developed a plug-and-play pathway refactoring workflow for rapid discovery of natural products. 7 This workflow consists of two-step Golden Gate reactions that The glycocin BGCs were predicted from genomic sequences that are available in NCBI (National Center for Biotechnology Information) by RODEO, and genes for glycocin biosynthesis were annotated. (B) The candidate BGCs were then refactored using a two-tier strategy, and the resulting products were detected using MALDI-TOF MS. For color coding, see Figure 2 . Cysteines that are predicted to form disulfide bonds are highlighted in yellow. Residues that are predicted to be glycosylated are highlighted in purple. The mutated residues of the precursor peptide from L. monocytogenes SLCC2540 BGC to prevent proteolysis are highlighted in green. Both of these residues were mutated to alanines.
first convert biosynthetic genes into individual expression cassettes and then assemble these expression cassettes into one plasmid. In this work, we adapted this workflow for discovery of new glycocins (Figure 1) . Briefly, the target glycocin BGC was first partially refactored, which involves only the peptide precursor gene and the glycosyltransferase gene that are required to generate a glycosylated intermediate (first tier). 9 If a compound corresponding to the expected intermediate was detected, the corresponding BGC was then fully refactored to generate the final product (second tier). E. coli BL21(DE3) was used as a heterologous expression host, and the BGC genes were codon optimized for E. coli and obtained through DNA synthesis. For the refactored partial glycocin BGC, after overnight culture in 1 mL of media under various temperatures, the resulting cell pellets were obtained by centrifugation and homogenized in an ultrasonic bath. For the refactored full glycocin BGC, supernatants instead of cell pellets were used for next step analysis. Both the supernatants and the cell lysates were desalted and analyzed by MALDI-TOF MS (matrix assisted laser desorption/ionization-time-of-flight mass spectrometry). While this workflow was designed for the discovery of glycocins, it is also potentially applicable for highthroughput discovery of other RiPP families in the future.
Refactoring of Glycocin BGCs for Heterologous Expression in E. coli. Putative glycocin BGCs were predicted by RODEO. The amino acid sequence of the glycosyltransferase for sublancin (SunS) was used as the query for BLAST, and the top 5000 hits were used as the input for RODEO, which analyzed the neighboring genes of each input gene in batch through comparison against the Pfam pHMM database. All putative glycosyltransferases with their neighboring genes were then filtered by the typical features of the glycocin BGCs as described in the Materials and Methods. A sequence similarity network was then generated for the putative precursor peptides, and six BGC candidates for refactoring were mainly chosen from different groups in this network (Figure 2a and S1a). Two out of these six glycocin BGCs were chosen because of their extremophile origin (thermophilic strain, Geobacillus sp. 8 and alkaliphilic strain, Bacillus sp. JCM19047), which may offer better stability of the product glycocins under certain conditions for future applications ( Figure 2 and Figure  S1a ). 10−14 According to the sequence of the precursor peptides, these glycosins belong to the same group as that produced by the BGC from B. megaterium BHG1.1.
The first tier pathway refactoring was performed as indicated in Figure 1B . Both the precursor peptide and glycosyltransferase were expressed as individual expression cassettes with a T7 promoter and T7 terminator. After the first tier pathway refactoring process, three out of the six partial glycocin BGCs expressed in E. coli generated peaks in the MALDI-TOF mass spectrum with molecular weights corresponding to the monoglycosylated precursor peptides ( Figure S2a ). Based on the mass increase compared to the nonglycosylated precursor peptide (162 Da), all the installed sugars were hexoses. The partial glycocin BGC from Listeria monocytogenes generated a new peak in the mass spectrum consistent with a diglycosylated precursor peptide with an N-terminal truncation. To confirm this result, we introduced site-specific mutations (K7A and M8A) at the putative cleavage sites on its precursor peptide and coexpressed the mutant precursor gene with the glycosyltransferase (Figure 2b ). The expected full length mutant precursor peptide with two hexoses installed was indeed observed in the MALDI-TOF mass spectrum ( Figure  S2b ). Given the successful glycosylations, all four glycocin BGCs were then fully refactored with every biosynthetic gene expressed as an individual expression cassette with a T7 promoter and T7 terminator ( Figure 1B ). Of note, for the glycocin BGC from L. monocytogenes, the mutant precursor peptide gene was used in pathway refactoring. New peaks in the mass spectrum corresponding to the glycosylated precursor peptides with their leader peptides removed at the expected sites (Figures 2b and S4) were observed from the desalted supernatants ( Figure 3) . The resulting four glycocins were named bacillicin CER074, bacillicin BAG2O, geocillicin, and 
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Isolation and Structural Characterization of the Glycocins. To obtain sufficient amounts of glycocins for structure characterization and bioassays (at least 40 μg for each glycocin for both MS based structural characterization and standard agar diffusion assay for bioactivity screening), we further optimized cultivation conditions and purified the glycocins through ammonium sulfate precipitation, solid phase extraction, semiprep HPLC, and analytical HPLC (Figure 3b ). The existence of disulfide bonds was first confirmed by an iodoacetamide (IAA) assay that demonstrated the absence of free thiols ( Figure S5 ). 9 The purified glycocins were then digested by chymotrypsin under nonreducing and reducing conditions and analyzed by MS. Through assignment of the observed fragments, we concluded that all four glycocins shared similar topologies ( Figure S6 ). Although the glycosylated residues for the three SunA/ThuA-type glycocins can be easily assigned to the third cysteine by the results of iodoacetamide derivatization and proteolytic digest, MS/MS analysis was necessary to determine the glycosylated residue in listeriocytocin. Through sequence alignment, Ser60 in the precursor peptide of listeriocytocin was predicted to be glycosylated (Figure 2b ). MS/MS data confirmed this prediction and showed that two successive glycosylations occur on Ser60 (Figure 4 , Figure S7 , and Figure S8 ).
To further determine the type of hexoses installed in the four glycocins, the glycosylated precursor peptides were purified from the corresponding partial BGCs, which resulted in a higher yield than refactoring of the full BGCs ( Figure S3) . Notably, in the first tier pathway refactoring, the precursor genes were cloned into a helper plasmid with an internal Nterminal His-Tag at the cloning site ( Figure S11 ), which enables the purification of the glycosylated intermediates by immobilized metal affinity chromatography (IMAC). These intermediates were then further purified by reversed-phase high-performance liquid chromatography (RP-HPLC) and hydrolyzed. The sugars were derivatized and analyzed using gas chromatography as described elsewhere. 9, 15 In comparison with various hexose standards, all the installed sugars on these four glycocins were shown to be glucoses ( Figure 3D ). Previously, two glycosyltransferases for glycocin biosynthesis were characterized in vitro and exhibited promiscuous activity toward different nucleotide sugar substrates. 15, 16 Considering that the concentrations of some potential nucleotide sugar substrates, such as UDP-N-acetylglucosamine, are much higher than UDP-glucose in E. coli, 17, 18 it appears that the glycosyltransferases under investigation here have a preference for UDP-glucose. To further investigate if glycosyltransferases for glycocin biosynthesis exhibit high specificity for their nucleotide sugar substrates during heterologous production in E. coli, we also coexpressed the precursor peptide of enterocin F4−9 with its glycosyltransferase in BL21(DE3). A mass representing the peptide modified with two N-acetylglucos- amines was clearly observed by MALDI-TOF MS ( Figure S12 ) consistent with the known structure of enterocin F4-9. 2 Hence, glycocins with their native glycosylation can be produced in E. coli.
All three SunA/ThuA-type glycocins shared similar topology and sugar modification as sublancin ( Figure S6 ), suggesting these structural features are conserved in this glycocin family. Although enterocin 96 was the first discovered enterocin 96-type glycocin, its structure has yet to be elucidated. 19 Recently the glycosyltransferase of enterocin 96 was reconstituted in vitro, and the modification was shown to be a disaccharide. 16 As we discovered that the listeriocytocin was also diglucosylated at the same serine residue predicted to be glycosylated in enterocin 96 by sequence alignment, it is very likely that the wild-type enterocin 96 shares a similar structure as that produced in vitro, and the type of sugar modification might be glucose. The diglucosylation on one Ser might be a distinct feature of enterocin 96-type glycocins from other diglycosylated glycocins, such as enterocin F4-9 and glycocin F, which are glycosylated at two different residues. 20, 21 Listeriocytocin does have has some distinct structural features compared to enterocin 96, such as a much smaller loop size ( Figure S1c) .
Antimicrobial Activity of the Glycocins. The antimicrobial activity of the four glycocins was probed against a panel of Gram-positive and Gram-negative bacteria (E. coli JM109, Pseudomonas aeruginosa PA01, methicillin-resistant S. aureus NRS384/USA300, vancomycin-resistant E. faecium V583 CB807, L. monocytogenes 4b F2365, B. subtilis Δspβ, B. halodurans C-125, and B. cereus ATCC14579) by a standard agar diffusion assay (Table S1 ). Although listeriocytocin lacked antimicrobial activity toward all organisms tested, bacillicin CER074 and bacillicin BAG2O exhibited antimicrobial activity against B. cereus ATCC 14579 (minimal inhibitory concentrations: sublancin, 2.5 μM; bacillicin CER074, 0.156 μM; bacillicin BAG2O, 0.625 μM), and geocillicin also exhibited weak bioactivity ( Figure 5) . Overall, the three newly discovered SunA/ThuA-type glycocins have narrower antimicrobial spectrum than sublancin with all of them inhibiting the growth of B. cereus ATCC14579, but not other bacilli tested ( Figure S9 and Figure S10 ).
As the bioactivity of glycocin F, which is a glycocin decorated with two N-acetylglucosamine (GlcNAc) moieties, can be reversed by free GlcNAc, 22 we tested if free glucose can have a similar effect on the antimicrobial activities of the four new glycocins. While the bioactivities of sublancin and geocillicin could be reversed by free glucose, no significant effects were observed for bacillicin CER074 and bacillicin BAG2O, which means these two glycocins might have different target(s) from sublancin and geocillicin ( Figure 5 ). Previous studies showed that sublancin's activity is mediated by the phosphoenolpyruvate:sugar phosphotransferase system (PTS) and the large mechanosensitive channel of conductance MscL. 23, 24 In structure−activity relationship (SAR) studies, Arg33 of sublancin was previously shown to be critical for its bioactivity against B. subtilis Δspβ, and most of the SunA/ ThuA-type glycocins are positively charged at the corresponding site in a sequence alignment to sublancin. 9 However, bioactivity was also observed for bacillicin BAG2O that does not contain a corresponding charged residue, which may imply that bacillicin BAG2O has a different target(s) from sublancin. Therefore, it would be of great interest to further investigate the antimicrobial mechanisms of these new glycocins, and our production platform in E. coli provides the opportunity to perform further SAR studies.
■ CONCLUSION
In this work, we used a rapid pathway refactoring workflow to discover four novel glycocins from various origins, which has significantly expanded the glycocin family. This workflow is potentially scalable, which can be very helpful for RiPP discovery in the future. We provide evidence that diglycosylation might be a general feature for enterocin 96-type glycocins, and the bioactivity assays demonstrate that factors besides the topology and type of glycosylation may affect the bioactivities of glycocins, which is of great interest for further investigation of structure−function relationships.
■ MATERIALS AND METHODS
Materials and Reagents. All chemicals were purchased from Sigma-Aldrich and Thermo Fisher Scientific. E. coli NEB 10-beta was used for DNA manipulation and E. coli BL21(DE3) was used as a host for expression. Genes were obtained as gBlocks from Integrated DNA Technologies. BsaI, T4 DNA ligase and other restriction enzymes for checking the assembly of plasmids were obtained from New England Biolabs, while the BpiI was obtained from Thermo Fisher Scientific and the T7 DNA ligase was obtained from Enzymatics. Plasmids were isolated using QIAGEN Plasmid Mini Kit. Kanamycin was used at 50 μg/mL for all E. coli cultures. ZipTip C18 was purchased from EMD Millipore. All sequencing grade peptidases were obtained from Promega.
Genome Mining by RODEO. The amino acid sequence of SunS (the glycosyltransferase for the biosynthesis of sublancin) was used as the query for BLASTP, and the first 5000 hits were used as the input for the analysis by RODEO. Each predicted gene cluster was filtered by the existence of all genes which are necessary for glycocin biosynthesis (genes encoding SunA-like precursor, SunS-like glycosyltransferase, disulfide bond formation protein/thioredoxin gene, SunT-like transporter). The gene encoding a peptide less than 100 aa with at least 4 cysteines was considered as the putative precursor gene.
Pathway Refactoring through the Plug-and-Play Workflow. The pathway refactoring process followed the protocol we described before with slight modifications. 7 In the partial pathway refactoring, a new helper plasmid (T7 His Helper 1) with an internal N-terminal His-tag at the cloning site was used in the first tier Golden Gate reaction for cloning the precursor gene, while the glycosyltransferase gene was cloned into the T7 Helper 2/9 plasmid. In the full pathway refactoring, the precursor gene, the glycosyltransferase gene, the Detection of the Glycosylated Precursor Peptide from Cell Pellets and Glycocin from Liquid Medium by MALDI-TOF MS. For the partial refactored BGCs, cells were grown in LB medium, and IPTG was added to 0.5 mM when the OD600 reached 0.6−0.8. Cells were grown with shaking at 18, 30, and 37°C in parallel for overnight induction. Cell pellets were harvested from 1 mL of liquid culture by centrifugation and resuspended in 100 μL of cell lysis buffer (8 M urea, 50 mM Tris·HCl, pH 7.5), which were then vigorously vortexed three times (30 s each time) and sonicated in an ultrasonic bath (Branson 2800, Danbury, CT) for at least 30 min. The supernatants were then collected by centrifuge, desalted by ziptip, and analyzed using MALDI-TOF MS. For the fully refactored BGCs, the supernatants of liquid culture were collected by centrifugation after overnight induction, desalted by ziptip, and analyzed using MALDI-TOF MS. As rich media are too complex, which largely affect the product detection from the supernatant possibly due to ion suppression (data not shown), minimal medium M9 was used in the full BGC refactoring.
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